Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine

HW Chesson, JF Laprise, M Brisson… - The Journal of …, 2016 - academic.oup.com
Background. We estimated the potential impact and cost-effectiveness of providing 3-doses
of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13–18 years …
被引用次数：38 相关文章

Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine.

HW Chesson, JF Laprise, M Brisson, LE Markowitz - 2016 - cabidigitallibrary.org
Background. We estimated the potential impact and cost-effectiveness of providing 3-doses
of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years …

Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.

HW Chesson, JF Laprise, M Brisson… - The Journal of …, 2016 - europepmc.org
Background We estimated the potential impact and cost-effectiveness of providing 3-doses
of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years …
[HTML] nih.gov

[HTML][HTML] Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV …

HW Chesson, JF Laprise, M Brisson… - The Journal of …, 2016 - ncbi.nlm.nih.gov
Background. We estimated the potential impact and cost-effectiveness of providing 3-doses
of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13–18 years …

Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine

HW Chesson, JF Laprise, M Brisson… - Journal of Infectious …, 2016 - hero.epa.gov
BACKGROUND: We estimated the potential impact and cost-effectiveness of providing 3-
doses of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 …

Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine

HW Chesson, JF Laprise, M Brisson… - The Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Background We estimated the potential impact and cost-effectiveness of providing 3-doses
of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years …

[引用][C] Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV …

HW Chesson, JF Laprise, M Brisson… - Journal of Infectious …, 2016 - cir.nii.ac.jp
Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine
Among US Females Previously Vaccinated With 4-Valent HPV Vaccine | CiNii Research …

Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.

HW Chesson, JF Laprise, M Brisson… - The Journal of …, 2016 - europepmc.org
Background We estimated the potential impact and cost-effectiveness of providing 3-doses
of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years …